MARKET

CYDY

CYDY

Cytodyn Inc
OTCMQB
0.4100
+0.0260
+6.77%
Closed 15:59 05/13 EDT
OPEN
0.4150
PREV CLOSE
0.3840
HIGH
0.4459
LOW
0.3915
VOLUME
4.71M
TURNOVER
1.93M
52 WEEK HIGH
0.4945
52 WEEK LOW
0.1031
MARKET CAP
505.30M
P/E (TTM)
-42.7083
1D
5D
1M
3M
1Y
5Y
1D
CytoDyn's new data shows leronlimab could treat solid tumors
Seeking Alpha · 4h ago
CytoDyn announces data on mechanism of action of leronlimab
TipRanks · 10h ago
CYTODYN INC: PRELIMINARY EVIDENCE SUGGESTS LERONLIMAB HAS POTENTIAL TO TURN "COLD" TUMORS "HOT"
Reuters · 11h ago
CYTODYN ANNOUNCES DATA SUGGESTING NOVEL MECHANISM OF ACTION OF LERONLIMAB FOR THE TREATMENT OF SOLID TUMORS
Reuters · 11h ago
Weekly Report: what happened at CYDY last week (0505-0509)?
Weekly Report · 1d ago
CytoDyn appoints Robert Hoffman as CFO
TipRanks · 05/06 12:36
CYTODYN INC - APPOINTS ROBERT E. HOFFMAN AS CHIEF FINANCIAL OFFICER
Reuters · 05/06 12:30
Press Release: CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
Dow Jones · 05/06 12:30
More
About CYDY
More
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.
Recently
Symbol
Price
%Change

Webull offers CytoDyn Inc stock information, including OTCMQB: CYDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYDY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYDY stock methods without spending real money on the virtual paper trading platform.